Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials

BACKGROUND: Laquinimod 0.6 mg is a once-daily, oral, disease-modifying therapy in development for the treatment of multiple sclerosis (MS) that was investigated in two double-blind, placebo-controlled, phase 3 trials: ALLEGRO and BRAVO. METHODS: Data from these studies were pooled to assess the safe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J MS Care
Autors principals: Sørensen, Per Soelberg, Comi, Giancarlo, Vollmer, Timothy L., Montalban, Xavier, Kappos, Ludwig, Dadon, Yuval, Gorfine, Tali, Margalit, Maya, Sasson, Nissim, Rubinchick, Svetlana, Knappertz, Volker
Format: Artigo
Idioma:Inglês
Publicat: The Consortium of Multiple Sclerosis Centers 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315319/
https://ncbi.nlm.nih.gov/pubmed/28243182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2015-024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars